Crossmark

Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)

Crossref DOI link: https://doi.org/10.1007/s00262-025-04126-9

Published Online: 2025-08-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Costantini, Adrien

Takam Kamga, Paul

Pons-Tostivint, Elvire

Fradin, Delphine

Emile, Jean-François

Giroux-Leprieur, Etienne
License Information

Text and Data Mining valid from 2025-08-26

Version of Record valid from 2025-08-26
More Information

Article History

Received: 27 January 2025

Accepted: 21 June 2025

First Online: 26 August 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below